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腿 T R A C T 
〜 Epirubicin has been used as an anticancer agent in 七he 
treatment of inoperable hepatocarcinoma in which case it is 
administered as an aqueous solution intravenously after 
reconstitution of 七he fac七ory—packed dry powder. Pharmacokinetic 
analysis of the current method of mixing the aqueous solution 
directly with Lipiodol, an oily contrast medium， and injecting 
the mixture intra—ar七erially does not reveal any significant 
clinical superiority over the aqueous solution, although some 
； 々 -
degree of targeting effect was suggested. This could probably be 
due to a lack of pharmaceutical consideration and technology in 
the formulation of the preparation. 
An oil/water emulsion containing epirubicin for 
parenteral' administration has been developed with due 
consideration given to basic principles of pharmaceutics and 
formula七ion- The stability of the emulsion, sterility, rate of 
drug release, toxicity, and pharmacokinetics after 
administration into rabbits were studied and reported. 
Ejctraction of epirubicin from various media was 
performed by a modified assay based on earlier reports. 
Determination of the drug and its metabolite in plasma samples 
was carried out by high performance liquid chromatography. 
Different pharmacokinetic parameters， obtsLined from plasma 
concentrations using computer programmes, were used to compare 
the disposition of epirubicin after intravenous and intrahepatic 
injections of the emulsion and solution of the drug. 
Findings india七e 七 h a t since a lower area under 七he 
curve (AUG) was obtained after intrahepatic injection of 七he 
formulated emulsion, a targeting effect is possible. It may 
therefore enable intrahepatic administration of larger doses of 
epirubicin with perhaps less systemic side effects. 
广 ， 
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CHAPTER I: TNTRODUCTION AND SOMK DISPOSITION PRINCIPLES 
Since the early 1980s， many research projects 
have been devoted to the special formulation of 
antineoplastic agents for 七 he treatment of 
hepatocarcinoma (1 一 9). One area of interest is the 
use of special formulations together with a selected 
route of administration in order to obtain a targeting 
effect on the tumour. However, results have not been 
too encouraLging in terms of clinical improvement and 
reduction in side effects, 
A review of 七he previous reports shows a possible 
reason for unsatisfactory results : a lack of 
consideration of pharmaceutical formulation in the 
development of the solutions. Many factors should be 
considered when an oil is added to an aqueous solution 
of anticancer agents in the design of an emulsion. 
In the present study, we are interested in 
developing an emulsion for irrbra—arterial injection in 
order to obtain a targeting effect on liver tumour 
cells. In view of past experience, most of 七 h i s 
•thesis is devoted to the formulation of an emulsion 
based on phai>maceu七ical principles. 
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In 七 his study, a lipid contrast medium for 
lymphography Lipiodol, was chosen to be the oil phase 
of 七 he emulsion due to its unique property of 
preferential uptake by hepatoma cells and retention for 
a prolonged period of time after intrahepatic injection 
(10, 11), It was mixed with an aqueous solution of 
epirubicin, an anticancer agent, and formulated into an 
emulsion with 七he use of emulsifying agents. 
EPIRUBTCTN 
Epirubicin is a potent antineoplastic agent of the 
anthracycline group. Pharmacologically it is 
classified as an antibiotic ari七ineoplastic agerrb. Its 
structural analog, doxorubicin (Adriamycin), has 
already been shown to ‘ be effective in treating 
hepatoma at the cost of a considereible degree of 
cardiotoxicity. 
Anticancer activity of epirubicin is due mainly to 
its affinity for DNA, with irrbercala七ion into the 
D M double helix structure (12, 13). This completing 
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with double-stranded DNA results in disruption of 
nucleic acid synthesis and function, due to inhibition 
of the biochemical processing of template DNA by DNA 
polymerase (14). 
Currently, epirubicin is indicated in the following 
neoplastic conditions (15): 
1. mammary carcinoma 
2. malignant lymphomas 
3. soft tissue sarcomas 
4. gastric cancer 
Preliminary evidence of efficacy has been found in 
malignant melanoma and advanced colorectal carcinoma. 
When given in combination with other cytotoxic agents, 
it is also found to be able to induce therapeutic 
response in lung and ovarian cancers (15). 
Although hepatocellular carcinoma is not ye七 a 
proven indication for epirubicin therapy, preliminary 
evidence has shown some degree of therapeutic response 
» 
(9， 16， 17). 
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Pharmacokinetically, epirubicin has uptake and 
distribution comparable with doxorubicin, yet with a 
lower tissue concentration, suggesting an increased 
hepatic metabolism and/or a higher renal clearance of 
epirubicin (18). Metabolism of epirubicin gives 
several metabolites vrtiich can be detected in plasma and 
urine after administration ， the major one being 13 
epidoxorubicin (13 - OH). Due to low water solubility 
of the free base, epirubicin is currently supplied in 
the form of hydrochloride salt for in 七 ravenous 
administration• 
A number of techniques for the detection of 
epirubicin and its metabolites in .plasma have been 
reported in the literature (19, 20), but high— 
performance . liquid .. chromatography (HPLC) with 
fluorescence detection appears to be the best method as 
it is reproducible and can also differentiate be七ween 





Emulsions are defined as heterogeneous systems of 
one liquid dispersed in another in the form of 
droplets. The two liquids are immiscible, chemically 
un2?e£LC七ive and form systems characterized by little to 
no thermodynamic stability. 
When two immiscible liquids are mechanically 
aigi七a七ed， both phases 七 e n d to form droplets which 
greatly increase the free surface energy of 七 h e system, 
and at such a high energy level the system becomes 
unstable. Through the process of coalescence this free 
surface energy again attains its minimum value. If a 
stable emulsion is to be formed, an emulsifying agent 
(emulgen七/emulsifier) must be added, which by its 
presence at the interface prevents coalescence of 七he 
globules. It acts by reducing the interfacial tension 
and hence decreasing 七 h e interfacial free energy 
produced on dispersion. Another more impor七arvb role 
to act as an interfacial barrier which, by being 
present in sufficiently high concentration, will 
> 
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produce a rigid film between the two immiscible 
phases. The film may thus act as a mechanical barrier 
both to flocculation and to coalescence of the emulsion 
droplets. 
The material that is dispersed into small particles 
or exists as globules is termed the internal, disperse 
or discontinuous phase. The other material is known as 
the external phase, continuous phase, or dispersion 
medium. 
The most common types of pharmaceutical emulsion 
include water as one of its phases and an oil or other 
liquid as the other. If the oil droplets are dispersed 
in a continuous cL<3.u.eous phase， the emulsion is termed 
oil-in-water type (o/w), if the oil is the continuous 
phase, the emulsion is of the water - in - oil type 
(w/o). The oil and water phases need not be single 
components， each phase may coiTtaiiri a multitude of 
ingredients. Most pharmaceutical emulsions designed 
for oral administration are of 七 h e o/w type, while 
externally used emulsions such as creams and lotions 
are either o/w or w/o depending on their use. For 七 h e 
purpose of 七he present study, we shall concen七ra七e on 
emulsions for parenteral use. 
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Emulsions for parenteral use are usually o/w type, 
especially when they are for intravenous or intra-
arterial use, to avoid the risk of thromboembolism. An 
oil soluble medicament is dissolved in a suitable 
carrier and the mixture is emulsified to form the final 
preparation. However it is essential, but relatively 
difficult, to achieve stable droplets of less than 4 urn 
in order to prevent emboli in the blood vessels C23). 
Another limitation on injectable emulsions is the 
requirement for sterility， as conventional 
bactericides are contraindicated in large volume 
parenteral injections, and autoclaving has been the 
traditional method of sterilization for parenteral 
emulsions. Regardless of the limitations, a number of 
such emulsions have been designed and used clinically. 
Intravenous fat emulsions using lecithins and non-ionic 
surfactants as emulsifying agents are the most commonly 
used examples. 
Although oil soluble drugs are usually incorporated 
in the oil phase of an oil-in-water emulsion for 
parenteral use, there have been studies showing 七 h a七 
water — soluble drugs can also be administered in 
emulsion form, resulting in enhanced absorption (24, 
25). This is probably because a portion of 七he drug is 
bound to the oil droplets. 
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stability has always been the major concern 
in the formulation of an emulsion. Instability may 
appear as one or more of the following situations: 
a. Creaming 
This is the separation of the emulsion into two 
layers， one layer containing more of 七he disperse 
phase. The layer can be redispered by shaking. It 
can be avoided by reducing the size of globules and 
increasing 七he viscosity of the continuous phase. 
b. Cracking 
This involves the irreversible coalescence of the 
dispersed globules and separation of the disperse 
phase as a separate layer. Redispersion cannot be 
achieved by shaking and the preparation can no longer 
be used. It may result from using 七he incorrect 
combination or proportion of emulsifying agen七s， 
chemical or microbial degradation, addition of a common 
solveivb， incorrect method of addition of electrolytes, 
improper storage temperature, and significant changes 
in pH. 
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c. Phase inversion 
Phase inversion occurs as the amount of 
disperse phase is increased until it approaches or 
exceeds the theoretical maximum of 74% (37) of the 
total volume, when the emulsion changes from o/w to 
w/o or from w/o to o/w type. 
SOME PRINCIPLES OF DRUG DI5P0STTT0N 
The analysis on the disposition of a drug is mainly 
based on the pharmacokinetic parameters obtained from 
analyses. Unlike pharmacology， the subject of 
pharmacokinetics describes, expresses and predicts the 
absorption, distribution, metabolism and elimination of 
a drug using symbols and mathematical equations. It is 
therefore a science of the relationships be七ween the 
movement of a drug through the body and the processes 
affecting it. 
The body can be viewed to be composed of a very 
large number of compartments. A compartment, in 
pharmacokinetic terms， is those organs and 七 i s s u e s for 
which the rates of uptake and subsequent: clearance of a 
drug are similar. 
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For the purposes of this study, only expressions 
and relations describing non-compartment models are 
discussed. 
1. Bolus in七ravenous injection 
When a rapid single intravenous injection (a bolus) 
is given to a patieivfc， if we plot plasma 
concentration against time， we will find the 
concentration declines rapidly at first and then 
more and more slowly, and eventually comes very 
close to zero. (Fig (1) - 1) 
Concentration of drug 
Time 
Fig (1) - 1 
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The phenomenon can be described by the following 
equation: 
D 二 Do e-i^ t^ Eq. (1) 
where D = amount of drug in the body at time 七 
Do = initial amount of drug (七he initial dose) 
K = elimination rate constant 
Thus, the rate of elimination of the drug 
varies continuously depending upon its concentration 
at any given time (31). 
2. Volume of Distribution/Apparent Volume of Distribution 
The volume of distribution (Vd) of a drug does 
no七 refer to any real volume (31). It is 
simply the size of a compartment necessary to 
account for the total amount of drug in the body 
if it were present throughout the body in 
the same concentration found in the plasma. 
Mathematically, it can be expressed as 
Vd = D Eq. (2) 
Cp ‘ 
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where D 二 total amount of drug in the body a七 time t 
Cp = plasma concentration at time t 
Apparent volumes of distribution which are 
larger than the actual plasma compartment (i.e. 
greater than 3 litres) only indicate that the 
drug is also present in 七 i s s u e s or fluids outside 
that compartment (31). The actual sites -- of 
distribution cannot be determined from 七 h i s value. 
The apparent volume of distribution is a function 
of the lipid versus water solubilities and of the 
plasma and tissue protein binding properties of 
the drug. Factors which tend to keep the drug 
in the plasma or increase Cp, such as 
low lipid solubility, increased plasma protein 
binding, or decreased 七 i s s u e binding, 
reduce the apparent volume of distribution. 
It follows then that factors which decrease Cp, 
such as decreased plasma protein binding, 
increased tissue binding, and increased lipid 
solubility increase 七he apparent volume of 
distribution. 
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3. Bioavailability and Area Under the Curve (AUG) 
； « 
Bioavailability is the degree to which a 
drug is made available to a specific organ or 
tissue different from the site of absorption 
for a pharmacological response to occur. It is 
therefore apparent that the intensity and 
duration of the tissue response is probably in 
most cases a function of the 
concentration and persistance of the drug in 
the blood or plasma. 
Figure (1) - 1 represents a typical plasma 
concentration versus time plot for a drug 
administered intravenously. The area under the 
curve (AUG) i.e. the hatched area in Fig (1) 一 1， 
is a useful measure of the amount of drug absorbed 
into the systemic circulation (see Page 10). 
We would therefore expect the size and 
duration of 七he biological response to be related 
in some way to the size of this area. In other 
words, a measure of this area can be a useful 
index of the bioavailability of the drug. 
oo 
The AUG o from time zero to infinity can be 
obtained from Equation (3) 
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t 
OO t Cp 
AUCo : AUCo + —— Eq. (3) 
K 
where Cpt 二 plasma concentration at time t. 
K = elimination rate constant 
4. Clearance 
Clearance is 七 he volume of blood or plasma 
cleared of drug in a unit time. It is obvious 
that clearance must be related in some way to the 
volume in which the drug is dissolved (volume of 
distribution Vd) and the rate at which it 
leaves the body ( i.e related to the elimination 
constant K )• If a drug is cleared from the plasma 
by several processes then the total clearance is 
the sum of the individual clearances. Plasma 
clearance is expressed by the relationship 
CI = VaK Eq. (4) 
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Clearance is 七he sum of individual clearance values 
(31) 
Clp 二 CIM + CIR + CIH + Eq. (5) 
Where CIP = plasma clearance 
CIM = metabolic clearance 
CIR = renal clearance 
CIH = hepatic clearance 
Because plasma clearance is the product of 
eliminsition rate constant and volume of 
distribution (From Eq. (4) )， we would expect it 
to be closely related to the AUG (31). 
CI = Dose Eq- (6) 
oo 
AUG o 
5. Half - life (ti/s) 
The half 一 life is 七he time taken for 七he 
concentration of drug in the blood or plasma 
to decline to half of its orignial value. 工七 is 
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given that 
ti/2 : 0.693 Eq. (7) 
K 
Apart from the above, other parameters include the 
mean residence time (MRT) which is calculated from the 
ratio of AUMC/AUC where 
AUMC = area under the first moment curve (31)-
Also the steady state apparent volume of distribution 
(Vss) can be calculated from equation (8). 
Vss = Clp. MRT Eq. (8) 
All these principles will be used in the subsequent 
analyses of the different studies. The pharmacokinetic 
parameter's presented will be computed by the programme 
PKCALC (32). Significance of difference of kinetic 
parameters among the different treatment groups are 
evaluated using 七he S七udent^s, non-pair 七一七est, with 
P < 0.05 considered to be 七he limit of significance. 
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CAHPTER II ： DKTRRMTMATTON OF EPIRUBTCIN IN BIOLOGICAL 
FLUIDS 
1. INTRODUCTION 
Different methods have been developed for the assay 
of epirubicin in plasma (33， 34, 35). The experiments 
done by Moro et al in 1981， though sensitive and 
efficient, required the process of evaporation under 
reduced pressure (33)， and hence were more 
time-consuming and expensive. Later efforts 
incorporated an extraction procedure, and a minute 
amount of desipramine was added into the back-
extracting solution to avoid adsorption losses. 
However the retention times for epirubicin and its 
metabolite wiere relatively long requiring about 22 and 
18 minutes respectively (33). Also， no internal 
standard was included in the assay making the results 
questionable (34). Likewise, the method developed by 
Maessen et al in 1987 had similar long retention times 
(about 14 minutes for all compounds) in addition to 
irregular recoveries ranging from 49-75% (35). The 
assay developed for this project was based on a 





The chromatography system comprises of a Waters 
501 pump (Waters 一 Associates, Milford, Mass, 
U.S.A.), a 7125 injector (Rheodyne. Calif, 
U.S.A.) and a variable wavelength Hewlett-
Packard HP1046A programmable fluorescence 
- 广 ， 
detecter (Hewlett-Packard， U.S.A.), and the 
results were recorded on a Linseis L6512 char七 
recorder (Linseis, Germany). Analyses were 
performed on a Nova-Pak reversed phase C18 
column ( 100mm x 8mm I. D., Waters Associates, 
Millipore, U.S.A.) held in a Waters RCM 
cartridge holder (Millipore, U.S.A.) linked to 
a Ce precolumn (packed with Perisorb RP-8 30-
40um, E- Merck, Germany). ‘Centrifugation was 
done in a Hitachi HIMAC SCR ISB centrifuge 
(Hitachi, Japan). 
Other apparatus include 10ml capacity 
centrifuge test tubes with well fitting screw 
caps (Pyrex, England), and ISml evaporation 
tubes with finely tapered bases of lOOul 
capacity (Sovirel, Levollois-Perret, France). 
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All test tubes were silanised by rinsing with a 
3% solution of hexamethyldisilazane (HDMS) in 
distilled chloroform 七o minimize loss of drugs 
to adsorption onto 七 h e glass wall. All 
glass wares were cleaned by soaking overnight 
in a 3% solution of Ex七ran (Merck, Darmstadt, 
Germany) in water， then rinsed thoroughly with 
methanol and hot tap water followed by 
distilled water. 
A 25ul Hamilton microsyringe was used during 
the extraction procedure while a 50ul one was 
used for injection into HPLC. 
B. Materials 
The following materials were used : 3-propanol, 
chloroform, sodium hydrogen phosphate and 
or 七 ho—：phosphoric aicid， all of analytic-
reagent (AR) grade (Merck， Germany). Water was 
double distilled in a glass apparatus. 
Epimibicin and doxorubicin were purchased from 
the agent of Farmatalia Carlo—Erba in Hong 
Kong in vials of lOmg for parenteral use while 
the metabolite, 13 一 epidoxorubicin (13 一 OH), 
19 LlJiJ：— n 
was supplied by the original manufacturer. 
Lipiodol was also purchased from the agent of 
Guerbet (France) in Hong Kong. Other materials 
used include polysorbate 20 (Tween 20), 
sorbitan monolaurate (Span 20)， poloxamer 
• (Sigma, U.S.A.) and acetonitrile (AR) grade 
(Merck, Darmstadt, Germany). 
广-
C. Chromatographic Conditions 
The mobile phase consisted of acetonitrile 35% 
in 0-05% phosphoric acid, with pH adjusted to 
3.5. The column was washed after each assay 
with acetonitrile 60% in double distilled 
water. Every time before use, both the mobile 
phase and the washing solution were filtered 
using a 0.45iim Millipore membrane (Waters 
Associates, Milford， Mass, U.S.A.). Filtration 
was assisted by a vacuum pump. 
Flow rate was adjusted to 2.2 ml/min. The 
fluorescence detector was set to the following 
conditions : excitation wavelength at 470 run, 
emission wavelength at 580nm, peak gain a七 11 
and temperature of assay is at room temperature 
20 
(about 250C)- The concentrations of epirubicin 
and 13-dihydroepirubicin (13 - OH) were 
calculated using the peak height ratios 
relative to the in七ernatl s七aLndaird-
D. Sample Preparation 
Plasma samples were obtained from 七 h e rabbit' as 
described in Chapter IV. Sample volumes 
ranging from 0.6 to 1.0 ml were pipetted into 
10 ml centi^ifuge test "tubes with screw-cap. If 
less than 1.0 ml， the volume was made up 
to 1-0 ml with double distilled water in 
each case. 15 ul of doxorubicin 100 ug/ml 
was used as the internal standard. One 
millilitre of sodium hydrogen phosphate (1.18 
G/lOOml， adjusted to pH 8.4) was added and 
the mixture was mixed by vortex mixer. 
Epirubicin was extracted by adding 4 
millilitres of a mixture of chloroform: 2-
propanol (3:1). The whole mixture was mixed 
, well with a rotating mixer for 30 minutes, and 
then centrifuged at 3000. revolutions/minute at 
200c for 15-20 minutes. Afterwards the 七 o p 
aqueous layer was discarded by pipette and the 
21 
bottom organic phase was transferred to a clean 
cen七i^ifuge tube. The drugs were back extracted 
by 0-15 millilitre of 0.1 M or七ho-phosphoric 
acid with lOug/ml of desipramine to avoid loss 
due to adsorption on glass wall. The mixture 
was mixed by a rotating mixer for 30 minutes, 
七 h e n centrifuged for 15 minutes. Afterwards the 
top aqueous layer was transferred by pipette to 
an evaporating tube and was again centrifuged 
for 15 minutes, 100 ul of the resulting 
solution was injected into HPLC for analysis. 
All compounds were eluted within 6 minutes. The 
whole extraction procedure required 
approximately 6 hours for a batch of 26 
samples. 
E. Calibration and Recovery 
Blank plasma samples were spiked with known 
amounts of both epirubicin and 13-dihydro-
epirubicin to give concentration ranges of 125， 
250， 500， 1000 and 2000 ng/ml. The samples 
were treated， extracted and analysed by HPLC as 
described above. Six calibration curves were 
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drawn by plotting mean peak heigh七 ratios of 
epirubicin and 13-dihydro—epirubicin to that of 
internal standard against the respective 
concervfcrations. Recovery was assessed by 
comparing peak heights in the chromatograms of 
extracted samples with those samples containing 
known concentrations of the drugs but without 
undergoing extraction procedure. In both 
cases, internal standard was only added just 
before injection into HPLC. 
F. Results and Discussion 
The retention times for 13 - OH， internal 
standard and epirubicin are 4.2, 4.8 and 5.2 
minutes respectively. The representative 
chromatograms of the compounds in standard 
solution compared to those in a sample extract 
are shown in Fig (2)-l. 
The detection limit of the assay ranged from 
125 ng/ml to 2000ng/ml, which compares favour-
ably with other assays (33-35). 
The recoveries of the compounds from spiked 
samples were calculated and they ranged from 
23 
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72.5 - 83.6 ( Table (2) - 1 ). Despite the 
additional back extraction step, recoveries are 
comparable to, if not better, than the previous 
reported methods (33-35). 
Calibration curves were plotted and found to be 
linear for all compounds from 125 ng/ml to 2000 
ng/ml with coefficients of regression better 
than 0.99 (Apendix I P. 131). 
The average between-day variability of the i 
J彳 
assay was 7.6% for epirubicin and 8.2% for 13 一 
OH (Table (2) - 2). 
RECOVERY (mean土SD) % (n =6) 
125ng/ml 250ng/inl 500ng/ml lOOOhg/ml 2000ng/inl 
Epi 73.4±9 77.7土12 80.0土9 72.5土8 81.3土11 
130H 80.0土10 75-0土10 80-2土10 80.0土7 83.6土12 
Table (2) - 1 ： Recoveries of Epirubicin and epidoxorubicinol (13-OF： 
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Compound Coeff. of Variation of concentrat ions % (n 二 6) 
125ng/ml 250ng/inl 500ng/inl lOOOng/ml 2000ng/ml Mean 
Epirubicin 10.3 7.7 7.9 6.2 5.9 7.6 
13 - OH 12.4 9.8 8.4 5.1 5.3 8.2 
Table (2) - 2 : Between 一 Day variability of the assay 
G. Conclusion , 
A rapid and economical method of extraction and 
assay was developed. The sensitivity of 七he 
assay was comparable to methods reported 
earlier. The recovery is satisfactory, 
taking into considerai七ion 七he fate七 that two 
extraction steps were employed in the 
procedure. The accuracy and reproducibility 
are - also saitisfaLC七ory as seen in 七 he 
calibration curves and the between-day 
variability, though there is the n e c e s s i t y of a 
daily run of standard samples when analysing 
samples with unknown concentrations. 
In conclusion， 七 h i s assay is suitable to 
perform pharmaicokinetic studies of both 七he 
paren七 drug and the metaiboli七e in animal models 
as well as human subjects. 
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CHAPTER III : DISPOSITION OF EPIRUBICIN IN PATIENTF； 
WITH HEPATIC CARCINOMA 
1. INTRODUCTION 
Epirubicin， a stereoisomer of doxorubicin, has been 
shown in preliminary studies to be effective in 
treating hepatic carcinoma (9， 16， 17). However, using 
the conventional routes of administration, efficacy is 
limited by systemic toxicity. Various experimentail 
drug delivery systems， such as microspheres, liposomes 
and emulsions, have been described to provide means of 
targeting tumours with cytotoxic drugs (26， 27, 28). 
However, one method that apparently has not been 
explored is the direct mixing of an aqueous solution of 
a drug with an oil. Lipiodol, a lipid contrast medium 
has been shown to be taken up preferentially by 
hepatoma cells and is retained for a long period of 
time after injection into the hepatic artery (10， 11). 
This unique property has been exploited by 
incorporating bleomycin (29)， mitomycin-C and 
adriamycin (30) to Lipiodol for targeting purposes. I七 
is therefore suitable for use as the oily phase in 




Fourteen male patients (age between 34 and 69 
years old of Chinese origin)， with 
histologically proven hepatoma or hepatomegaly 
with a-fetoprotein level above 500 ug/L, wei^ e 
recruited for this study. They had not 
previously been treated with chemotherapy or 
radiotherapy and had no serious concurrent 
illnesses. Eight of these patients were given 
epirubicin-Lipiodol complex of whom three 
received more than one course of treatment 
(七he second course at七 SL higher dose) and three 
patients received only intrahepatic plain 
epirubicin for comparison. Three other 
patients on 3 separate occasions received 
intravenous and intrahepatic-arterial plain 
epirubicin, and intrahepatic-arterial 
injection of Lipiodol-drug complex (Table (3)-
1). The Lipiodol-epirubicin complex was 
prepared aseptically by dissolving the 
prescribed dose of epirubicin with 2 ml of 


























































































































































































































































































The emulsion was formed by mixing 七 h o r o u g h l y 
within the syringe followed by ultra-
sonification. The preparation was infused 
percutaneously into 七he hepatic artery under 
X-ray monitoring according to Seldinger's 
me七hods (44) immediately after preparation. 
Patients received 50 mg m一2 or 70 mg m一2 of 
epirubicin. Blood samples were drawn before 
treatment and a七 5， 15， and 30 min and at 1， 
2， 4， 8， 12， 24， 48 and 72 hr after 
administration. Serum samples, separated 
after cen七rifuga七ion， were stored at -20^ 
before analysis. 
2.2 Assay 
The method of assay is as described in 
Chapter 11. 
3. RESULTS 
Comparison of disposition between IA plain 
epirubicin and lA Lipiodol-epirubicin 
Figure (3)-l compares the mean serum 
concentration-time profile of epirubicin in 8 
patients who were given in七ra—arterial (lA) 
Liipiodol-epirubicin with that from 3 patients given 
lA plain epirubicin. 
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Fig(3)-1 : MEAN SERUM CONCENTRATION—TIME PROFILE OF EPIRUBICIN 
AFTER 工 A - L E ADMINISTRATION IN 8 PATIENTS AND 工 A - E 
ADMINISTRATION IN 3 PATIENTS 
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鲁 
Table (3)-2 summarises the mean kinetic parameters. 
It is apparent that, though the number of patients 
compared was small, there was a difference in some 
pharmaco kinetic parameters between these two 
o o 
groups. The AUG o is higher in the lA Lipiodol-
epirubicin group (lA-LE)， while the clearance is 
faster, and elimination half-life and mean 
residence time shorter in the lA-plain group (lA-
E). 
Serum concentration-time profiles of IV, lA 
epirubicin 
The serum-concentration-time curves of 
epirubicin after intreivenous (IV) and in七rsOiepaitic— 
arterial (lA) injection of plain epirubicin， and lA 
administration of Lipiodol-epirubicin in 3 patients 
(LMT， CKW and KCN) are shown in Figure (3)-2. The 
derived pharmsicokinetic parameters are summarised 
in Table (3)-3. It appeared that the relative 
bioavailability of epirubicin after lA plain 
epirubicin and lA Lipiodol-epirubicin in 七 h e three 
patients was variable. 
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Table (3) - 2 Mean {+S.D.) kinetic paraieters of epirubicin after 
intrahepatic-arterial injection of plain epirubicin 
(lA-B) and Lipiodol epirubicin (lA-LK) 
INTRAHEPATIC-ARTEEIAL EPIRUBICIN 
PARAMETERS lA-E (n : 3) lA - LE ( n : 8) P < 
00 
- 1 -
AOC (ng il h) 0.50 (0.1) 0.84 (0.2) 0.025 
0 
-1 -1 
CI (ilh Ig ) 3.69 (1.3) 1.84 (0.5) 0.01 
-1 
Vss (L Kg ) 65.3 (23.1) 48.8 (9.6) 0.25 
HRT (h) 17.6 (1.6} 28.0 (8.8) 0.05 
1/2 


























































































































































































































































































































































































































































































































































































































































TABLE (3-3) Kinetic parameters of epirubicin in 3 patients after 3 
separate doses; intravenous (IV-E), and intrahepatic 
arterial (lA-E) plain epirubicin, and intrahepatic-
arterial (lA-LE) Lipiodol-epirubicin. 
PARAMETERS PATIENTS 
LMT CKW KCN 
IV-E lA-S lA-LK IV-E lA-S IV-LE IV-E lA-E IV-LE 
00 
-1 
AOC (ugal -h) 1.71 1.36 1.30 1.98 1.44 0.90 1.30 1.38 1.56 
0 
- 1 - 1 
CL (alh Kg ) 1.43 1.80 1.89 1.41 1.94 3.10 2.20 1.88 1.63 
-1 
Vss (L Kg ) 46.80 46.50 68.20 42.90 82.90 95.60 53.60 71.00 78.00 
MRT (h) 32.70 25.90 36.20 30.40 42.80 30.90 26.70 37.70 46,70 
T (h) 27.40 20.20 27.70 23.80 32.90 24.10 22.80 29.50 36.30 
1/2 
Bioavailability - 0.80 0.76 - 0.73 0.45 - 1.06 L20 
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Fig(3)—3 : MEAN SERUM CONCENTRATION—TIME PROFILE OF EPIRUBICIN 
AFTER HIGH DOSES AND LOW DOSE lA-LE ADMINISTRATION 
IN 3 PATIENTS 
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Comparison of disposition between high and low dose of 
IA Lipiodol—epirubicin 
Figure (3)-3 compares the mean serum 
concentration-time profiles of high and low dose 
epirubicin after lA Lipiodol-epirubicin in the same 
3 patients. There is no apparent difference in the 
overall pharmacokinetic parameters (Table (3) - 4)， 
oo 
the AUG o, Vss, MRT and elimination tiZ2 of 
epirubicin were bigger in the high dose group, 
though not statistically significant. 
4. DISCUSSION 
The present study has shown several important 
aspects of epirubicin kinetics in patients with 
liver cancer after IV and lA administraLtion of 
plain epirubicin and Lipiodol-epirubicin complex. 
The study, however, was hampered by small patient 
groups； thus it is difficult to assess the 
usefulness of the Lipiodol-epirubicin complex to 
give a clear picture. Patients suffering from 
cancer in 七 h i s study were not easy to recruit. 
Initial 七 r i a l s did include a large number, however, 
because of the nature of the disease some of 七 h e m 
passed away before the next cross-over study. 
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When intra arterial injection of ‘ plain 
epirubicin (lA-E) was compared with that of 
Lipiodol-epirubicin (lA-LE) in two different 
patient groups, there were significant differences 
in some of the pharmacokinetic parameters (Table 
(3)-2. Such difference cannot be confidently viewed 
as an effect of the formulations on epirubicin 
kinetics for several reasons. Firstly the patient 
numbers were small. Secondly, a true comparison of 
epirubicin disposition can only be obtained in 
crossover experiments as demonstrated by the 
studies on patients LMT, CKW and KCN (see Table 
(3)-3). Thirdly the hepatic function of patients 
with liver cancer might not be stable during the 
disease period and epirubicin is largely eliminated 
by liver metabolism. The elimination of epirubicin 
and its metabolites are impaired in liver 
dysfunction (45). 工七 was noted that in a cross-
over study on 七 h e comparative metabolism and 
pharmacokinetics of epirubicin and adriamycin, a 
wide variation of metabolic elimination of the 
epirubicin existed among patients and the 
elimination of both drugs was signif icari 七 ly 
impaired in one patient who had hepatic metastases 
40 
and percutaneous biliary drainage because of 
extrahepatic obstruction (45). Furthermore, the 
Lipiodol-drug complex might not have been 
homogeneous, the drug release from the complex was 
not controlled. It is likely that epirubicin might 
not be trapped in or uptaken by the hepatoma via 
the Lipiodol. 
From the cross-over study in 3 patients "who 
were, on 3 occasions (one month apart)， given IV 
and lA plain epirubicin and lA Lipiodol-epirubicin 
- 2 
70 mg m the relative bioavailability of 
epirubicin is higher ( = 1) in one patient， KCN, 
(Table (3)-3). It is likely the liver function 
might be modified by the disease state over a 
period of 3 months. It is interesting to note that 
the bioavailability of Lipiodol-epirubicin is lower 
than epirubicin in the other 2 patients. In all 3 
patients, the intravenous plain epirubicin was 
given as the last dose of the 3 occasions while 
Lipiodol-epirubicin was given as the first dose. 
Assuming the liver function of patients LMT and CKW 
41 
was not altered throughout 七 h e study period, the 
I 
lower bioavailability of epirubicin after the lA-LE 
aidministrsLtiori suggested some ,evidence of 
targeting. The hepatoma might have, trapped the 
Lipiodol-drug complex, thus systemic availability 
was reduced. The IV data were comparable to 
published da七a (46)， though patients were of 
Caucasian origin and with different types of 
‘ . 广-
cancer. In a separate cross-over study of three 
patients who received high and low doses of the • 
oo 
Lipiodol-drug complex, slightly larger AUG o and 
longer elimination half life of epirubicin were 
detected after high dose (Table (3)-4), indicating 
a dose - related change in the pharmacokinetics of 
the preparation. 
The present study did not give a clear 
indication whether the Lipiodol-epirubicin complex 
would give lower blood concentrations of the drug. 
oo 
. The reduction in AUG o in the cross-over study of 
three patients might be due to a successful 
七 rapping of the drug to ILipiodol which was 
selectively taken up by the hepatoma or a change in 
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In conclusion the present study reveals new 
information to 七he disposition of epirubicin after 
intra arterial administration of Lipiodol-
epirubicin complex (lA-LE). The lA-LE disposition 
was comparable with that of intravenous and intra 
arterial injection of plain epirubicin. Probably 
i七 was related to 七 h e absence of emulsifying agent 
in the Lipiodol—epirubicin complex. Further “ 
studies are needed to include a better 
formula七ion of the complex in order to study the 
targeting effect toward hepatoma by Lipiodol. 
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CHAPTER IV ： DKSTQN OF THE EMULSION FOR INJECTION 
PRINCIPLES OF DOSAGE FORM DESIGN 
Drugs are almost always given in formulated systems 
which vary from relatively simple solutions to more 
complex preparations such as subcutaneous implants. 
Formulation is achieved by the use of appropriate 
additives or ingredients, with the help of special 
technique of compounding if necessary, to provide 
various pharmaceutica1 functions and achieving various 
therapeutic purposes. Hence the principal objective of 
dosage form design is to achieve a predictable 
therapeutic response to a drug included in a 
formulation with reproducible product quality. 
There are many factors for consideration in the 
successful incorporation of a drug into a specific 
dosage form. These factors can be broadly categorized 
into three groups: 
1- Biopharmaceutical considerations: these include 
七 h e dosage form, the route of administration， 
sterility, release of drug from 七 h e dosage 
form， and particle size, etc. 
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2, Physical and chemical properties of the drug: 
factors to be considei^ed include the pH, pKa 
value, stability， compatibility with other 
ingredients, solubilities in oil and water, 
etc. 
3. Clinical considerations including the acute and 
chronic toxicity of the formulation, me七hoc;! 
of administration, and methods of dose 
monitoring, e七c. 
For the purposes of 七 h i s study, we shall concentrate on 
the biopharmaceutical factors. 
BIOPHARMACKUTICAL CON^TDERATTON^ 
1. Dosage form 
Epirubicin is only available in injectable form 
and therefore any dosage form design using this 
drug will be based on this preparation. 
In this project, the parenteral route is preferred 
for 2 reasons: 
46 
a. an SLntineoplastic agent is best given 
intravenously to minimize gastrointestinal 
upset, increase bioaLvailaibility and attain a 
more predictable blood concentration in a 
comparatively shorter period of time. 
b. depending on 七he site of administration, an 
antineoplastic agent can be targeted at certain 
neoplasm in specific organs by choosing the 
artery supplying the organ for injection. By 
limiting the outflow of drug from the specific 
organ due to accumulation after selective 
uptake, much higher doses can be given with a 
lower degree of systemic toxicity. 
In many emulsions designed for injection， 
an oil-soiuble medicament is dissolved in a 
suitable carrier and the mixture is emulsified to 
form the final preparation. An extra advantage of 
adopting an emulsion for administration is that the 
high surface area of dispersed oil globules will 
enhance the rate of absorption of lipophilic 
drugs ( 39 )• Emulsion for intravenous use must be 
47 
of the oil—in—water O/W type (Chapter I) to avoid 
the formation of emboli whereas water-in-oil (W/0) 
type emulsions can be administered intramuscularly 
to produce a depot effect. The choice of 
emulsifying agents is based msiirily on on their 
efficacy, toxicity， use of final product and the 
other materials required to be present. 
1.1 Choice of oil phase 
Konno e 七 al ( 1 — 8) demonstraL 七 ed an 
accumulation of a lymphographic agent, 
Lipiodol, in liver cancer cells, similar 
results were also reported by Novell et al 
(9 - 11 ). Lipiodol is an iodised poppy-seed 
oil and usual route of administration is by 
in七ramuscular injection and the normal dose in 
human for diagnostic purposes、is 0.15 ml/Kg 
(42 ). With this special accumulative effect, 
together with its low reported toxicity, it 
was chosen to be the oily phase in the 
emulsion for this project. 
1.2 Choice of Emulsifying Agents 
A suitable emulsifying agents for oil - in -
48 
water (O/W) emulsion must be 
chosen. Emulsifying agents of the non-ionic 
surfactant type are often used in the 
preparation of parenteral emulsions due to 
their low toxicity and irritancy (23)， and 
also a greater degree of compatibility when 
mixed with oil and water. The only 
disadvantage is that they tend to be more 
expensive. 
Non-ionic surfactants can exhibit both 
hydrophilic and hydrophobic properties due to 
their surface active character. By varying 
the relative proportions of components, 
products of different texture can be produced. 
If the hydrophobic part of the molecule 
predominates then the compound will have 
greater solubility in oil, and hence will 
migrate and concentrate in the oil phase which 
becomes the continuous phase of an emulsion, 
producing a water-in - oil (W/O) emulsion. 
Similarly a surfactant with higher water 
solubility will give an oil-in-water (O/W) 
emulsion. 
49 
The best type of non-ionic surfactant to use 
is therefore one with an equal balance of 
hydrophilic and hydropholic properties. 
Common examples include lecithin, 
polysorbates, methylcellulose, gelatin and 
serum albumin. In this project， non-ionic 
surfaic七sirrbs — a polysorbate with a sorbi七sin 
ester， were chosen for the following reasons: … 
a. compatible with most anionic, ca七ionic and 
non-ionic materials 
b. neutral pH 
c. stable to the effects of heat， pH changes, 
and high concentrations of electrolyte 
d. low systemic toxicity 
Polysorbates are polyethylene glycol 
derivatives of sorbitan esters. They have 
the general formula : 
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H 2 — 4 ) Z R 
( S U M O F W / X , Y A N D Z IS 20; 
R IS (CiiH23)C00 ) 
General Formula of Polysorbates 
where R represents a fatty acid chain. 
Variations in the type of fatty acid used 
and in the number of oxyethylene groups 
in the polyethylene glycol chains 
produces a range of products of differing 
oil and water solubilities. 
Sorbitan esters are produced by the 
esterification of one or more of the 
hydroxy1 groups of sorbitan with either 
lauric, oleic, palmitic or stearic acid. 
They have the general formula 
51 
R - COOCH2 ^ ^ 
HO OH 
OH 
General Formula of Sorbitan Esters 
where R represents a fatty acid chain. 
To increase the stability of an 
emulsion, polysorbates are generally used 
in conjunction with the corresponding 
sorbitan ester to form a complex 
condensed film at the oil/water interface 
(39). 
For this project, polysorbate - 20 and 
its corresponding sorbitan ester, 
• sorbitan monolaura七e， were chosen to be 
the main emulsifying agents because of 
superior solubility in water, and hence 
a greater tendency to produce an oil -
in - water (0/W) emulsion than other 
analogs ( 39 ). 
» 
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stability of the emulsion can be enhanced 
by 七 h e addition of stabilizers. One 
group of commonly used stabilizer in 
emulsion are the poloxamers which are 
employed in intravenous fat emulsions and 
as solubilising agents to maintain 
clarity in elixirs and syrups. They are 
a series of non-ionic polyoxyethylene 
polyoxypropylene copolymers with the 
general formula 
HOCCsH^)^ - (CsHeO)^ - ((C2H40)c - H 
where a = c. An additional advantage of 
including poloxamer into the emulsifying 
system is : that poloxamer may increase 
the absorption of fat-soluble substances 
( 39 ). Thus for the purpose of this 
project, it might help to facilitate the 
uptake of lipid-soluble drug molecules 
into cancer cells and secure a 
targeting effect. 
53 
2. Route of administration 
A satisfactory response and a high degree of safety 
were demonstrated in addition to a targeting effect 
when antineoplastic agents were injected via the 
hepatic artery or the hepatic portal vein for the 
treatment of unresectable hepatocarc inomas 
( 1 - 9 ). Moreover, this method should produce a 
much higher concentration of drug in the liver 
circulation yet a lower degree of systemic 
toxicity due to lower systemic plasma 
concentration after accumulation. The hepatic 
portal vein is therefore chosen to be the site of 
administration for the emulsion. It is preferred 
to the hepatic artery due to its more superficial 
anatomical position in rabbits， which are the major 
experimental models in this study. 
P H Y S I C A L A N D C H E M T C A T . " P R O P E R T T K R O F T H R T)MIR. 
% 
In this project, epirubicin in the form of its HCl 
salt is used during the entire study due to the 
unavailability of its free base. 
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1- Chemistry of epirubicin 
Chemical data of epirubicin HCl are as follows 
(15 ): 
Structural formula : 
Q OH COCHoOH 
、、、OH 
OCH3 • OH h Z 、、、• 





Chemical formula : CayHaeNOiiHCl 
Molecular weight : 579.98 
Physical properties : red-orange, practically 
odourless， crystalline 
powder. 
Solubility : soluble in water and 
DMSO， slightly soluble in 
absolute ethanol, practi-
cally insoluble in non -
polar solvents. 
Melting point : V77。C with decomposition 
pH : pH of a 0.5% aqueous 
. solution is 4.0 - 5.5 
+ 
pKa : pKa of the NHs group, 
determined by aqueous 
titration at 25<=>C with 0. IN 
NaOH is 7.7 
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2. Stability and compatibility of the formulated 
emulsion compared to that of an aqueous solution. 
According to the data supplied by the original 
manufacturer, a reconstituted solution retains up 
to 98% of its potency in 24 hours when stored at 
room temperature. It is also recommended that 
aqueous solution may be stored for up to 48 hours 
if refrigerated after reconstitution. 
It is recommended that epirubicin should not 
be mixed with heparin due to incompatibility due 
to possible chemical reactions, and it should not 
be mixed with other antineoplastic agents in the 
same intravenous fluid or the same syringe. 
These factors were thoroughly considered in 
the development of the formula for epirubicin 
emulsion and careful observations was taken every 




One of the major concerns in developing a dosage 
form is its toxicity 一 both acute and chronic. Since 
this project involves a cancer chemotherapeutic agent, 
chronic toxicity is probably of less significance 
because the drug is usually given as bolus doses in 
short periods of time. Hence emphasis should be placed 
on detection of acute toxicity. A thorough study of 
this is described in Chapter V. 
The actual method of administration and dose 
monitoring in human subjects should be determined in 
conjunction with clinicians involved in future clinical 
trials. 
THE FORMULA OF • FMIT.^TDN 
The ingredients of the emulsion were discussed in 
earlier parts of this chapter and this sec七ion deals 
mainly with the determination of the percen七aige of each 
ingredient in the formulation. 
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1. Percentage of oil 
Pharmaceutically, it is not easy to stabilize an 
emulsion containing less than 20% disperse phase 
since creaming would occur readily (36). A higher 
disperse phase concentration would result in a 
hindrance of movement of the droplets and hence a 
reduction in rate of creaming. On the other hand, 
although it is theoretically possible to include as 
much as 74% of an internal phase, it is usually 
found that at about 60% concentration phase 
inversion occurs (36， 37). The next point of 
consideration is, of course, the degree of toxicity 
offered by this range of percentage of oil and this 
is revealed by the studies on acute toxicity 
described in Chapter V. From this, a much higher 
IiD-50 was obtained for the emulsion with 25% of oil 
incorporated. Together with the consideration that 
a higher percentage of oil might necessitate a 
higher percentage of emulsifying agents, hence a 
higher possibility of toxic effects, we therefore 
set the level of oil at 25% (V/V). 
2- Percentage of emulsifying agents 
When a polysorbate and its corresponding sorbitan 
ester are used as the emulsifying system in an 
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emulsion, the recommended total percentage normally 
ranges from 5% - 12% ( 23， 29 ). Taking into 
consideration possible systemic toxicity， 5% was 
chosen as the concentration for 七he emulsion; this 
would be increased if stability proved to be a 
major problem. 
The proportions of polysorbate - 20 and sorbitan 
monolaurate in this 5% (W/V) of emulsification 
system is calculated using the Hydrophile -
Lipophile Balance (HLB) method (40). 
Calculation : 
Required HLB value of oil in an 0/W emulsion = 12 
HLB value of polysorbate 20 = 16.7 
HLB value of sorbitan monolaurate = 8.6 ( 41 ) 
Let X = % of sorbitan monolaurate in the mixture 
where 100-x = % of polysorbate 20 in 七he mixture. 
Contribution from sorbitan monolaurate = x 8.6 
1 0 0 ‘ 
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(100 - X ) 
Contribution from polysorbate 20 : x 16-7 
Since the total required HLB is 12 
X (100 - X ) 
(——8.6) + [ X 16.7] 二 12 
100 100 
X = 58% 
Therefore sorbitan monolaurate will occupy 58% 
(W/W) and polysorbate-20 will occupy 42% (W/W) of 
七he total 5% of the mixed emulsifying system in the 
emulsion. 
As for poloxamer, a concentration of 2.2% (W/V) 
had been used in studies as the only emulsifier 
with no toxicity reported ( 39 ). In this 
project,七he concentration is set at 2% as its 
role in this case is an emulsion stabilizer. 
With the above considerations, the initial formula 
of the Lipiodol - epirubicin emulsion is as 
follows: 
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Lipiodol 25% V/V 
Polysorba七e 20 } 
} 5% W/V 
Sorbitan monolaurate } 
Poloxamer 2% W/V 
Epirubicin 10 mg 
Water for injection to 5 ml 
THE METHOD OF PREPARATION OF THE EMULSION 
The preparation was carried out in a multiple-dose 
vial of 10 ml capacity. 
Procedure: 
1. Lipiodol was added into the vial. 
2- Suitable quantities of polysorbate 20, sorbitan 
monolaurate and poloxamer were weighed directly 
into the vial. 
3- About 3 ml of water for injection was used to 
i?econs七itute the epirubicin, the mixture was then 
shaken until completely dissolved. 
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4. The epirubicin solution was added to the Lipiodol -
emulsifiers mixture. 
5. Water for injection was added to adjust to the 
final volume. 
6. The emulsion was placed in an ultrasonicator (42, 
43) 七o facilitate complete dissolution of the 
solids and breaking down of the oil phase into 
smaller globules. 
7. The whole product was filtered using a 0.2 urn 
disposable sterile membrane filter, and collected 
into a pre-sterilized multiple-dose vial. 
BIOPHARMACTUTICAL STUDIES ON THK FORMITT.ATKP EMIJT.STON 
1. RELEASE OF DRUGS FROM THE FORMULATED EMULSION 
The rate of release depends mainly upon 七he 
oil/water partition coefficient of the drug and its 
rate of diffusion across the oil phase. The 
release of epirubicin when it is incorporated in an 
emulsion can be demonstrated using a diffusion 
63 ir 港 、 、 V . : i ：： ’:“ ••V. 
cell mounted on a cell-driving console and 
maintaining 七he temperature at 37oC ( human body 
temperature) using a warm water circulator. 
1.1 Method and Materials 
A 七 VTO—compsir 七 merit diffusion cell (Advanced 
Pharmaceutical Systems, Inc.， New Jersey, 
U.S.A.) was mounted on a cell-driving console. 
One cell (referred to as cell A) was filled 
with 2.5 ml of an isotonic pH 7.4 phosphate 
buffer while 七he other cell (cell B) was 
filled with 1 ml of epirubicin emulsion 
(concentration: 2 mg/ml) plus 1.5 ml of the 
same buffer as cell A. The 2 cells were 
separated by a molecularporous membrane 
(Molecular Weight Cut-off MWCO 12,000 -
14,000) (Spectrum Medical Industries Inc.， 
Calif., USA). Warm water at about 37^C was 
circulated around the cells by a water-
circulator . 
The magnetic stirrer was turned on and samples 
of 20 ul were taken at time 0 (control), and 
30 minute intervals thereafter up to 6 hours 
from both cells A and B. 
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The same procedure was repeated using 
epirubicin aqueous solution (concentration : 2 
mg/ml) in place of epirubicin emulsion in cell 
B. Extraction and analysis using HPLC were 
carried out according to the method described 
in Chapter 11. The whole experiment was 
repeated three times. 
1.2 Results and discussion 
The results of HPLC analysis are shown in 
Table (4) - 1 (Appendix 11). The comparison 
between the release of drug from the 
formulated emulsion and plain solution is 
shown in Fig. (4) 一 1 which shows the 
decrease in concentration of epirubicin from 
the original preparations. The rate of 
diffusion of drug across the membrane, hence 
the increase in concentration of epirubicin in 
the buffer solutions in each case is 
demonstrated in Fig. (4) 一 2. 
From the graphs it is apparent that the 
diffusion ability of epirubicin is not 
impaired after its incorporation into the 
formulated emulsion although there is a one-
hour delay before any epirubicin from emulsion 
enters the buffer. Yet from Fig. (4) - 2， it 










































































































































































































































































































































































































































































































































diffusion of epirubicin from the emulsion is 
somewhat slowed down, though no七 to a 
significant level. 工七 should also be noted 
that after 6 hours, the final concentration 
attained in buffer is somewhat higher for 
epirubicin solution than emulsion. Hence 
there is a possibility that some drug 
molecules are trapped in oil globules 
resulting in a lower diffusion rate and 
diffusion ability over the 6 一 hour period. 
2. GLOBULE SIZE OF OIL IN AN OIL-IN-WATER (O/W) 
EMULSION. 
The globules of an O/W emulsion for intravenous or 
intra-arterial use must be kept smaller than 4 um 
to avoid the formation of emboli ( 23 ). 
Traditionally， this can be achieved through a 
careful selection of emulsifiers and emulsion 
stabilizers. 
In this project, at special me 七 hod was 
developed to break 七 h e oil phase into smaller 
globules, hence producing a more stable emulsion 
and reducing the risk of emboli on administration-
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2 . 1 Method 
The finished product was drawn into a 10 ml 
syringe. A 0.2 urn disposable sterile 
membrane filter (S&S， Germany) was 七 h e n 
attached to the syringe. The emulsion was 
then slowly filtered through 七he membrane 
and the filtrate was collected in a 
sterilized injection vial. Examination of 
七 h e particle size was done under a 
microscope with the help of a graticule. 
2.2 Results and Discussion 
Microscopic examination of 七he filtrate 
revealed a majority (about 80%) of the 
dispersed oil globules was in 七he range of 
1一3 urn in diameter. Although saife七y for 
administration is not absolutely guaranteed， 
the risk of causing emboli should be 
considerably less than a simple mixing of 
aqueous phase and oily phase by 
ultrasonification• Moreover, the method 
provides a convenient and economical way to 
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sterilize the preparation at the same time 
as oil globules are reduced in size because 
it is recommended by the Pharmaceutical 
Codex that sterilization by filtration must 
be done with filter of the pore-size range 
0.2 - 0.22 urn ( 36 ). 
3. STABILITY OF THE FORMULATED EMULSION 
According to 七he manufacturer's recommendation 
(15)， epirubicin injection， after reconstitution, 
retains up to 98% of its potency for 24 hours at 
room temperature, and for 48 hours in a 
refrigerator (4 - IQoC)• The present project 
incorporates epirubicin into an emulsion, and it is 
interesting to find out whether the presence of 
other ingredients in 七 h e formulated emulsion would 
influence 七he stability of epirubicin. 
3.1 Method 
Epirubicin emulsion was prepared and samples were 
taken right after preparation and 24, 48, 72 and 
96 hours afterwards， the preparation was 
70 
o 
refrigerated at 2 - 4 C 七 h i r o u g h o u t , and the study 
was repeated 3 times • Extraction and analysis by 
HPLC were performed as described in Chapter II. 
3.2 Results and discussion 
The results of HPLC analysis are shown in Table 
(4) - 2， and Figure (4) - 3 demonstrates the 
stability of 七 h e drug when kept at 0 - after 
reconsti七ution. Results show that after 
epirubicin is incorporated in an emulsion, its 
stability is apparently unaffected. As a matter 
of fact, it is quite reasonable to say that it is 
jus七 as stable as a solution if it is kept 
refrigerated right after reconsti七ution. 
Time Emulsion Emulsion Emulsion Mean 
(hr. ) A B C S.D. 
0 53.1 52.1 51.55 52.25土0•78 
24 52.4 50.3 50.8 51.17土1.10 
48 50.8 52.3 51.4 51.5土0.62 
72 49.2 47.9 49.7 49.1+0.93 
49.6 48.4 48.4 48.8+0.69 
Table (4) 一 2 ：Concentration (mg/ml)of Epirubicin 




































































































































4. ACCELERATED STABILITY TESTS 
The stability of refrigerated epirubicin emulsion 
has been established. It will also be of interest 
to know whether other adverse storage conditions, 
of which temperature being the most significant 
one， would induce an accelerated disintegration of 
the emulsion. 
4.1 Method 
The formulated emulsion was prepared and it 
was then placed in an incubator， temperature 
being set at 20<^ C (room temperature) . Samples 
of 20 ul were drawn at time 0， then 24， 48, 72 
and 96 hours afterwards. Extraction and 
analysis were performed according to the 
•procedure discribed in Chapter 工工. The same 
was repeated with temperature set at 60oC. 
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4.2 Results and Discussion 
Results of the tests are as listed in Table 
(4) - 3 and Table (4) - 4. Figure (4) - 4 
shows when compared with the stability test 
done previously, the disintegration of 
epirubicin emulsion appears to be enhanced 
with increassing temperature. Therefore it is 
important to refrigerate the emulsion after 
preparation and 48 hour appears to be a 
reasonable shelf-life for the formulation if 
kept refrigerated. 
Time Emulsion Emulsion Emulsion Mean 土 
(hr. ) A B C S.D. 
0 5 1 . 9 5 5 2 . 0 5 5 2 . 2 5 2 . 1 土 0 . 1 3 
24 4 7 . 2 4 7 . 4 4 6 . 0 7 4 6 . 8 5 土 0 . 7 2 
48 4 6 . 9 4 7 . 1 3 9 . 5 4 4 . 5 土 4 . 3 3 
72 4 5 . 4 4 7 . 2 4 5 . 6 4 6 . 0 6 土 0 . 9 9 
96 4 4 . 3 4 2 . 9 4 3 . 8 4 3 . 7 土 0 . 7 1 
Table (4) - 3 Concentration (ng/ml) of Epirubicin 
Emulsion at 20^C 
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Fig(4)-4 : COMPARISON OF STABILITY OF EPIRUBICIN 
EMULSION MAINTAINED AT DIFFERENT TEMP-
eratures 
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Time Emulsion Emulsion Emulsion Mean 
(hr.) A B C 土 S-D. 
0 5 7 . 3 5 6 . 9 5 7 . 7 3 5 7 . 3 土 0 . 4 2 
24 5 0 . 3 4 7 . 2 5 0 . 4 4 9 . 3 土 1 . 8 2 
48 5 1 . 1 4 5 . 3 4 8 . 4 4 8 . 3 土 2 . 9 0 
72 4 8 . 3 4 5 . 1 4 6 . 4 4 6 . 6 土 1 - 6 1 
96 4 7 . 4 4 5 . 3 4 6 . 7 4 6 . 4 土 1 . 0 7 
Table (4) 一 4 Concentration (ng/ml) of 
Epirubicin Emulsion at 60^C 
5. STERILITY OF THE FORMULATED KMUT.STON 
As the emulsion will be injected either 
intravenously or directly into the liver via the 
hepatic portal vein, it must be maintained in a 
sterile state before and after the incorporation 
of epirubicin. Traditionally an emulsion for 
-injection is sterilized by either one of the 
following methods : ultra - filtration, dry / wet 
heat sterilization， irradiation or simply 
prepared using aseptic techniques. 
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5.1 Method 
Every time either a plain vehicle or a 
medicated emulsion was prepared, culture 
was done on nutrient agar and incubated at 37o 
C for 48 hours. 
5.2 Results and Discussion 
No microbial growth has been demonstrtated so 
far in any of the preparations. The absence 
of growth demonstrates 七he efficacy of the 
process of microfiltration by 0.2 urn filter 
membrane. Lack of microbial growth may also 
be due to the effect of epirubicin itself as 
it is a derivative of the anthracycline group 
of antibiotics. 
These findings enable us to avoid drastic 
sterilization procedures such as autoclaving. 
Nevertheless, the fact remains 七 h a t it is 
important for us to perform the admixture 
under a laminar flow hood and use glassware 
and utensils sterilized before use. 
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To conclude, the preparation should be safe in 
terms of sterility for intravenous 
administration into a peripheral vein or 
directly via the hepatic - portal vein. 
6. DEMONSTRATION OF HEPATIC UPTAKE AND RETENTION OF 
THE EMULSION 
6.1 Method 
The emulsion was prepared according to the 
method and formula described above. A rabbit 
was anesthesized by intravenous administration 
of pentobarbitone. 
A catheter was inserted into the hepatic 
portal vein after an incision was made in the 
thoracic - abdominal region. An appropriate 
dose of the emulsion was injected slowly 
through the catheter over 1-2 minutes. 
X - ray films were taken at time 0 which was 
the control, ri曲t after administration was 
completed, and at 1 , 2 , 5 and 10 minutes 
afterwards. 
The same procedure . was repeated with 
epirubicin 一 Lipiodol mixture (i.e. without 
the emulsifier system). 
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6.2 Results and Discussion 
The X - ray films taken using epirubicin 
emulsion are shown in Figure (4) 一 5 to Figure 
(4) - 10 while those using epirubicin -
Lipiodol mixture in Figure (4) - 11 to Figure 
(4) - 16. 
An obvious retention effect was observed as 
a considerable amount of the emulsion can still 
be seen in the liver lobes 10 minutes after 
administration- A selective uptake effect is 
possible because the image of the blood 
vessels is fading while the surrounding areas 
are becoming opaque as can be seen from 
Figures (4) - 4 and (4) - 5. This appears to 
be due to a facilitated entry of the oil into 
七he hepatocy七es after formulation into an 
emulsion, and drugs trapped in the oil 
globules could therefore be delivered into 
cells more efficiently. As for epirubicin -
Lipiodol mixture, a rapid disappearance is 
observed, indicating a rapid drainage of the 
fluid from 七 h e liver i.e. no re七en七ion effect 
was obtained. 
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Fig. (4) - 5 : Control before injectTion of emu is ion 
Fig. (4) - 6 : Immediately after injection of emulsion 
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m/ 
Fig. (4) - 7 : 1 minute after injection of Emulsion 
W • ^m 
Fig- (4) - 8 : 2 minutes after injection of Emulsion 
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m 
Fig- (4) - 9 : 5 minutes after injection of Emulsion 
m . 
Fig- (4) - 10 : 10 minutes after injection of Emulsion 
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Fig. (4) - 11 : Control before injection of Epi-Lip mixture 
Fig. (4) — 12 Immediately aif七er injection of Epi-Lip. mixture 
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Fig. (4) - 13 : 1 minute after injection of Epi-Lip mixture 
: — l U T 論 III _ _ 
Fig. (4) - 14 : 2 minutes after injection of Epi-Lip mixture 
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• 
Fig. (4) - 15 : 5 minutes after injection of epi-Lip mixture _ 
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Fig- (4) - 16 ： 10 minutes after injection of Epi-Lip mixture 
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CHAPTER V ： TOXICITY OF THR FORMTJT.ATKD EMULSION 
INTRODUCTION 
Discussions in this Chapter are based on the 
formula of the emulsion designed in Chapter IV- It is 
as follows : 
Lipiodol 25 - 50% 
Polysorbate 20 } 
} 5% ；、 
Sorbitan monolaurate } 
Poloxamer 2% 
Epirubicin 10 mg 
Water for injection to 5 ml 
Theoretically, every ingredient in the formulated 
emulsion should be tested for its toxicity. However, 
the individual acute toxicities of the active 
ingredient, epirubicin, and the system of emulsifiers 
have already been reported in literature (15， 47). 
For epirubicin, the dose in man is 1 mg/Kg body 
weight as recommended by the original manufacturer 
(15). In animal studies,七he range of LD50 in healthy 
mice when given intravenously was found to be 16 - 19 
mg/Kg (48), and in dog， single doses of 2 mg/Kg were 
found to be lethal (49). 
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For the three emulsifiers， namely polysorbate -20, 
sorbitan monolaurate and poloxamer, toxicity data was 
established by 七he World Health Organisation (WHO)(47). 
The three emulsifiers are all frequently used in 
food stuffs as food additives, the estimated accepted 
daily oral intake for man is 0 - 25 mg/Kg body weight 
calculated as total sorbitan esters- In rat, the LD50 
when given intravenously, was found to be 1,450 mg/Kg 
body weight and that for mice is 3,750 mg/Kg (47)". 
This can be compared to the quantity incorporated in 
the formulated emulsion， that is, a total of 5% of 
polysorbate 20 and sorbitan monolaurate. For an animal 
of say, 4 Kg, according to the dosage regimen of 1 mg 
epirubicin/Kg, the total amount of polysorbate 20 and 
sorbitan monolaurate injected is only 100 mg and 
therefore should be well within the safety margin. For 
poloxamer, 2% is incorporated in the emulsion, only 
80 mg is injected for an animal weighing 4 Kg and 
should therefore also be safe. 
For Lipiodol, the recommended intramuscular dose 
when used as a lymphographic agent is 0.15 ml/Kg (42). 
In the formulated emulsion, 25% of Lipiodol is 
incorporated. According to the same dosage regimen of 
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epirubicin, 0.5 ml of the oil is given parenterally 
for a 4 Kg animal subject (compare with 0.6 ml as 
recommended) and therefore should also be within the 
acceptable safety margin. What needs to be established 
is whether there is an enhanced absorption into cells 
after incorporation in an emulsion, and if there is, 
whether it would cause any additional toxicity. 
The above figures are calculated for ingredients in 
an emulsion according to each one's individual 
recommended dosages. As long as we are using an 
emulsion in our study, we need to assess the overall 
toxicity of the emulsion as a whole, to see whether 
there is any synergistic or antagonistic effect when 
the ingredients are mixed in such an emulsion. 
The study of the acute toxicity of the overall 
emulsion is conducted in 2 parts : one with the vehicle 
alone and the other after the active ingredient 
epirubicin is added. 
PART I : ACUTE TOXICITY STUDIES OF THK VKHTCT.K 
A. Background 
From the above discussion, it can be seen 七 h a七 七 h e 
concentration of the individual emulsifying agents 
is within safety margin, therefore at七en七ion is 
only focused on 七he toxic effect, if any, of 
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Lipiodol when it is administered in the form of an 
emulsion. 
Also as stated in the previous discussion， 
poloxamer 2% is added to the formula both as a 
stabilizing agent and for enhancement of 七 i s s u e 
uptake of the drug (39). To find out the possible 
potentiated toxic effect when poloxamer is added， 
separate toxicity studies have to be performed. 
Upon completion of this study, a formula with the 
lowest degree of toxicity can be determined. 
B. Method 
Different variations of the formulated emulsion 
were injected intravenously into the tail vein of 
mice and rats at increasing dosages. For rabbits, 
the emulsions were injected through the lateral ear 
vein- The number of deaths was recorded after 24 
hours and 七he time of occurence was noted if 
possible. The surviving subjects were also 
weighed after 24 hours. 
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C. Results 
Results of this study were assessed based on the 
normal dose of Lipiodol given as intramusculur 
injection : 0.15 ml/kg 
(i) Formula (1) 
Lipiodol 50%.> 
Polysorbate 20 2.1% } 
} 5% 
Sorbitan monolaurate 2.9% } 
Water for injection to 100% 
MICE 
Dosage Used Times of normal No. No. Lethal 
(ml/kg) dose of Lipiodol tested died rate (%) 
0.45 3 20 0 0 
0 』 6 20 0 0 
1-8 12 20 0 0 
2.7 18 20 0 0 
4.05 27 20 4 20 
4.5 30 20 5 25 
7-0 46.7 20 12 60 
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RATS 
Dosage Used Times of normal No. No. Lethal 
(ml/kg) dose of Lipiodol tested died rate (%) 
1.8 12 20 0 0 
3 . 6 24 20 0 0 
5 . 0 3 3 . 3 20 3 15 
6 . 0 40 20 4 20 
7 . 5 5 0 20 8 40 
8 . 5 5 6 . 7 20 1 1 55 
RABBITS 
Dosage Used Times of normal No. No. Lethal 
(ml/kg) dose of Lipiodol tested died rate (%) 
0 . 2 2 5 15 10 0 0 
0 . 3 2 . 0 10 0 0 
0 . 3 7 5 . 2 . 5 10 3 30 
0 . 4 5 3 . 0 10 6 60 
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Figure (5)-3 : Formula (1) 
T O X I C I T Y IN RABBITS 
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Discussion: 
From the graphs of Fig (5) 一 1 to Fig (5) -3, it was 
found that when Ijipiodol was given intravenously as an 
enrulsion produced according to Formula (1)， 
LD - 50 (mice) 二 6.25 ml/Kg 
(43 times the normal dose) 
LD - 50 (rats) =7.95 ml/Kg 
(53 times the normal dose) 
LD - 50 (rabbits) 二 0.42 ml/kg 
(2.8 times the normal dose) 
Data from this experiment suggested that the LD-50 
of Lipiodol for mice and rats when given intravenously 
are similar and weights taken 24 hours after injjection 
were also found to be similar as before. The LD 50 
value found in rabbit is much lower,七his is consistent 
with the observation in this study that rabbit has been 
more vulnerable to adverse effectsof 七 h e drug 七hain rat 
and mouse. The results obtained hence indicates 
toxicity of such a formulated emulsion is low. 
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(ii) Lipiodol 50% + Poloxamer 2% (mice, rats and rabbits) 
Formula (2) 
Lipiodol 50% 
Polysorbate 20 2.1% } 
} 5% 
Sorbitan monolaurate 2.9% } 
Poloxamer 2% 
Water for injection to 100% 
Results : 
MICE 
. Dosage Used Times of normal No. No. Lethal 
(ml/kg) dose of Lipiodol tested died rate (%) 
0.15 1.0 20 〇 0 
0.3 2.0 20 0 0 
0.6 4.0 20 0 0 
0.75 5.0 20 5 25 
0.9 6.0 20 17 85 
1.05 7.0 20 20 100 
RATS 
Dosage Used Times of normal No. No. Lethal 
(ml/kg) dose of Lipiodol tested died rate (%) 
0.15 1.0 20 0 0 
0.3 2.0 20 0 0 
0.6 4.0 20 2 10 
0-75 5.0 20 8 40 
0.9 6.0 20 19 95 
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RABBITS 
Dosage Used Times of normal No. No. Lethal 
(ml/kg) dose of Lipiodol tested died rate (%) 
0.15 1.0 10 0 0 
0.225 1.5 10 5 50 
0.3 2.0 10 10 100 
Discussion : 
From 七he toxicity graphs (Fig (5)-4 to Fig (5)-6), 
it was found that 
LD 50 (mice) 二 0.78 ml/kg (5.2 times the normal dose) 
LD 50 (rats) 二 0.77 ml/kg (5.1 times the normal dose) 
LD 50 (rabbits) 二 0.225 ml/kg (1.5 times the normal dose). 
It follows from the above findings that there is an 
obvious increase in toxicity after poloxamer is added 
to the formula. This is most likely due to an 
increased entry of oil into cells leading to necrosis 
or hemolysis- This can perhaps be eliminated by a 
reduction in the percentage of oil in the formula. 
t 
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TOXICITY IN RABBITS 
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(iii) Formula (3) 
Lipiodol 25% 
Polysorbate 20 2.1% } 
} 5% 
Sorbitan monolaurate 2.9% } 
Poloxamer 2% 
Water for injection to 100% 
Results : 
MICE 
Dosage Times of No. No. Lethal 
used normal tested died rate 
(ml/Kg) dose (%) 
0.15 1.0 20 0 0 
0.3 2.0 20 0 0 
0.45 3.0 20 0 0 
0.6 4.0 20 7 35 
0.75 5.0 20 10 50 
0.9 6.0 20 18 90 
1.05 7.0 20 20 100 
1 - 2 8.0 20 20 100 
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RATS 
Dosage Times of No. No. Lethal 
used normal dose tested died rate 
(ml/Kg) of Lipiodol (%) 
0 . 1 5 1 . 0 20 0 0 
0 . 3 2 . 0 20 0 0 
0 . 4 5 3 . 0 20 0 0 
0 . 6 4 . 0 20 6 -30 
0 . 7 5 5 . 0 20 7 35 
0 . 9 6-0 20 9 45 
1 . 0 5 7 . 0 20 17 85 
1 . 2 8-0 20 20 100 
RABBITS 
Dosage Times of No. No. Lethal 
used normal tested died rate 
(ml/Kg) dose (%) 
— —— — — —— — " — • — _ _ _ _ _ 
0 . 1 5 1 . 0 10 0 0 
0 . 2 2 5 1 . 5 10 3 30 
0 . 3 2 . 0 10 6 60 
0 . 3 7 5 2 . 5 10 . 10 100 
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From the graphs (Fig (5)-7 to Fig (5) -9)， it was 
found that when Ijipiodol was given intravenouisly as an 
emulsion produced according to Formula (3): 
LD - 50 (mice) 二 0•75 ml/kg (5 times the normal dose) 
LD - 50 (rats) =0.89 ml/kg (5.9 times the normal dose) 
LD 一 50 (rabbits) 二 0-27 ml/kg (1.8 times the normal、dose) 
Discussion 
Results from this study indicates that Formula (3) 
has a higher toxicity than Formula (1)， but a slightly 
lower toxicity than Formula (2). Therefore 七here is 
evidence suggesting that the higher toxicity is due "bo 
七he high percentage of oil. This could certainly be 
due to 七he presence of poloxamer as well. However, as 
poloxamer serves the dual purpose of being an emulsion 
stabilizer and facilitating the entry of lipid soluble 
drugs into cells, its benefits seem to be able to 
ou七vreigh its slight risk. 
Based on 七he above findings, the remaining parts of 
the research adopts Formula (3) as 七he standard formula 
for serving as a vehicle for antineoplastic agents. 
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PART 11 ： ACUTE TOXICITY STUDIES OF THE EMULSION AFTKT? 
EPIRUBICIN IS ADDFiD 
A. Background 
The toxicity of epirubicin in animal is well-
established as reported by the original 
manufacturer : intravenous LD50 in mice ranges 
from 16 - 19 mg/Kg (48)， and single doses of 2 
mg/Kg were lethal in dogs (49). 
In this study, toxicity of epirubicin when given as 
an emulsion is studied using mice, rats and 
rabbits. 
B. Method 
An oil—力n—water emulsion was'produced based on 七he 
following formula : 
Lipiodol 25% 
Polysorbate 20 2.1% 
Sorbitan monolaurate 2.9% 
Poloxamer 2% 
> 
Epirubicin 10 mg 
Water for injection to 5 ml 
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Increasing doses of the emulsion were injected into 
the tail vein of mice and rats and the lateral ear 
vein in rabbits. Results were recorded after 24 
hours, and those surviving subjects were weighed. 
C. Results 
Results from 七 h i s study were evaluated based on the 
normal dose of epirubicin : 1 mg/Kg as recommended 
by the manufacturer. 
MICE 
Dosage Times of No. No. Lethal 
used normal tested died rate 
(mg/Kg) dose of (%) 
epirubicin 
" " " " “ • • *• _ ‘ — “ I — — •__丨—• •隱 I • I • • 
1.0 1.0 20 0 0 
2.0 2.0 20 0 0 
2-5 .. 2.5 20 0 0 
3.0 3.0 20 0 0 
3.5 3.5 20 0 0 
4.0 4.0 30 9 45 
4-5 4.5 30 15 50 
5.0 5.0 20 15 75 
5-5 5.5 20 18 90 
6-0 6.0 20 20 100 
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RATS 
Dosage Times of No. No. Lethal 
used normal tested died rate 
(mg/Kg) dose of (%) 
epirubicin 
I • """" ^^ I “ _ "•“ •_• — • •"^― MM MM • I • • I -I I I • _ a^M 
1.0 1 10 0 0 
2.0 2 10 0 0 
3 . 0 3 10 0 0 
4 . 0 4 10 3 30 
4-5 4 . 5 10 4 40 
5 . 0 5 10 6 60 
5 . 5 5 . 5 10 8 80 
6-0 6 10 10 100 
RABBITR 
Dosage Times of No. No. Lethal 
used normal tested died rate 
(mg/Kg) dose (%) 
^ — — ^ — —» - — — _ ___ _ .1.1, 
—^ — — — — —— — 
1 - 0 1 . 0 10 0 0 
1 - 5 1 - 5 10 0 0 
2 - 0 2 . 0 10 1 10 
2 . 5 2 . 5 10 6 60 
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TOXICITY IN RABBITS 
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Disussion: • -
From Fig (5)—10 to Fig (5)—12, it was found that 
for epirubicin enmlsion : 
LD 50 (mice) 二 4.5 mg/kg (4.5 times the normal dose) 
LD 50 (rats) = 4.7 mg/kg (4.7 times the normal dose) 
LD 50 (rabbits) 二 2.4 mg/kg (2.4 times the normal dose) 
Although the result- in mice indicates a higher 
toxicity of epirubicin when given as an emulsion as 
compared to an aqueous solution: LD50 of 4.5 mg/Kg vs 
16 -19 mg/Kg (48)， it should still be safe when normal 
doses are given. 
From Fig- (5) 一 12， it can be seen that 七 h e LD -50 
for epirubicin emulsion when given intravenously in 
r^abbits is 2.4 mg/kg. This is some whsi七 lowei? than in 
mice， but bearing in mind that rabbit was observed to 
be more vulnerable to adverse effects of drug in 七 h e 
study, a LD - 50 which is only twice the normal dose is 
still acceptable. 
To conclude, the formulated emulsion appears to be 
safe for intravenous administration into 七 h e animal 
subjects， and is therefore adopted for subsequent 
kinetic studies in rabbits. 
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CHAPTER VI ： 
THE PHARMACOKTNKTIC 8TriPTK>S OF THE FORMULATED KPTRURTCTM RMfTT.^ TOH 
IN RABBTTP^ 
INTRODUCTION 
. From Chapter III， we notice the results of 
directly mixing epirubicin aqueous solution with 
Lipiodol were not pharmaceut ically or clinically 
satisfactory- In this chapter, studies were done by 
injecting the formulated epirubicin emulsion firstly 
in七ravenously， and secondly intraihepa七ically into 七 h e 
hepatic-portal vein of rabbits. The results are 
compared with those using plain epirubicin solution. 
PART I: INTRAVENOUS INJECTION OF EPIRUBICIN EMULSION 
.VS EPIRUBICIN AQUEOUS SOLUTION 
1. Method 
Cannulation was performed on 七he lateral vein and 
the central artery of the ear of 10 rabbits. 
Pentobarbitone 40 mg/kg was injected in七ravenously to 
produce anesthesia. Epirubicin aqueous solution, in 
dosage of 1 mg/kg (49)， was injected also intravenously 
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• • V 
after 5 -10 minutes. Blood samples were collected 
from the central artery at 0， 2.5, 5， 10， 15, 30， 60， 
120， 240， and 360 minutes after administration. 
Afterwards the cannulas were withdrawn and the surgical 
wounds were cleansed with alcohol 75%, and was 
securely wrapped with dressing. The subject was then 
brought back to the holding place followed by normal 
feeding. The same procedure was done with epirubicin 
emulsion using the same dosage. Extraction and 
quantitation by HPLC were performed according to 
methods described in Chapter II. Results were analysed 
using pharmacokinetic principles. 
PART II : INTRAHEPATIC INJECTION OF EPIRUBICIN EMULSION 
VS EPIRUBICIN AQUEOUS SOLUTION 
Method 
Cannulation was done on the lateral vein and the 
central artery of the ear of 8 rabbits. 
Pentobarbitone 40 mg/kg was used to anes七hesize 七he 
subjects by intravenous injection. 
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An incision was made on the abdomen of the rabbit. 
After a side-branch of the hepatic portal vein was 
located, epirubicin emulsion, in the dosage of 1 mg/kg, 
was injected slowly over one minute. Afterwards a 
bull-dog clamp was used to stop bleeding from the vein 
after the needle and syringe were withdrawn. Suture 
was done on the incision site and the subject was 
maintained in an anesthesized state. Blood samples were 
collected from the central artery at 0, 2-5， 5, 5， 
10, 15, 30, 60， 120, 240 and 360 minutes after 
administrsition. As cross-over study could not be 
performed on an operated rabbit, it was destroyed 
at the end of the experiment. 
Exactly the same procedure was carried out in 10 
separate rabbits but using epirubicin aqueous solution-
Extraction and quantitation by HPLC were performed on 
•the samples as described in Chapter II. Results were 
analysed using pharmacokinetic principles. 
RESULTS 
The plasma concentrations after the 2 different 
routes of administration of the 2 different dosage 
forms are shown in Appendix (III). 
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1. Comparison of disposition between IV epirubicin 
solution and IV epirubicn emulsion 
Figure (6) - 1 compares the mean serum 
concentration - time profile of epirubicin in 
rabbits after IV administration of emulsion and 
solution, and Table (6) 一 1 summarises the mean 
kinetic parameters. Some obvious differences were 
observed between the 2 groups of subjects. The 
oo 
o 
AUG is higher after IV solution while clearance 
is slower, 七he apparent volume of distribution 
smaller and elimination half-life and mean 
residence time longer. 
IV Emulsion (n = 10) IV Solution (n = 10) P< 
- 1 
AUC“ng ml min) 8054.7 (9003.9) 10846.1 (8731.9) 0.05 
- 1 - 1 
CI (ml min Kg ) 1561.9 (1422.6) 812.8 (687.7) 0.05 
- 1 
Vss (ml Kg ) 48783.2 (35956.9) 30908 (26532.8) 0.05 
MRT (min) 50.1 (30.3) 75.8 (125.6) 0_05 
1/2 
T (min) 37.7 (20.2) 63.4 (92.4) 0.05 
Table (6) 一 1 ： Mean (土SD) kinetic parameters of 
epirubicin after intravenous (IV) injection 
of emulsion and plain solution 
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o Fig(6)—1 : COMPARISON OF DISPOSITION OF EPIRUBICIN 
O AFTER IV INJECTIONS OF EMULSION AND 
S O L U T I O N 
1 1 8 
2. Comparision of disposition between IH injection of 
solution, emulsion and IV injection of solution of 
epirubicin-
Figure (6) - 2 compares the mean serum 
concentration-time profile after the 3 different 
modes of administration and Table (6) - 2 
summarizes the kinetic parameters. Intrahepatic 
injection of emulsion has 七he lowest AUG, but 
clearance is the fastest with 七he highest apparent 
volume of distribution. Though the values of 
half—lives do not differ to a significant degree, 
IH emulsion apparently has the shortest half-life. 
Bioavailability of IH injections is less than 50% 
indicating a high first-pass clearance by the 
liver. 
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- IH emulsion IH solution IV solution P< 
(n = 8) (n : 8) (n : 10) 
00 
-I 
ADC (ng ml sin) 2185 3831.2 10846.1 0.05 
0 
(1626,1) (1926.4) (8731.9) 
- 1 - 1 
CI (il sin Kg ) 3778 2701.8 812.8 0,02 
(3140.4) (2406.4) (687.7) “ 
-1 
V88 (si Kg ) 136673.8 128653.7 30908 0,05 
(80210.5) (89438.4) (26532.8) 
m (iin) 66.6 83,1 75.8 0.05 
(55.6) (75.7) (125.6) 
Ti/2 (Bin) 52.1 68.4 63.4 0.05 
(45.1) (59.3) (92.4) 
Bioavailability 0.2 0.36 L O 
Table (6) - 2 : Mean(+SD) Kinetic parameters of epirubicin after IH 
euulBion, Ifl solution and IV solution. 
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The study reveals some important differences of 
kinetic parameters in rabbits after IV and IH 
administration of plain epirubicin solution and 
formulated epirubicin emulsion. 
When intrahepatic injection of emulsion is compared 
七o IV injection of solution and emulsion, a significant 
degree of retention is demonstrated. Differences in 
bioavailability also suggest some degree of drug 
targeting is achieved. This might be even more obvious 
if hepatoma was present because neoplasms usually lack 
a clearing or drainaige system resulting in accumulation 
of drugs in cytoplasm of cells. This is an obvious 
improvement in the design of 七 h e formulated emulsion 
over 七he epirubicin—：Lipiodol mixture used previously. 
It is also important to note that the elimination 
half-life of in七rahepai七ic injection, whether emulsion 
or solution, is comparatively shorter. This could be 
due to the first pass metabolism of 七 h e drug after 
intrahepatic administration， as epirubicin is mainly 




The lower AUG o after intrahepatic injection may 
suggest that the amount of epirubicin in the general 
circulation is lower, and this may be related to lower 
systemic side effect of 七 h e drug. Thus, targeting 
hepatoma with the formulated epirubicin emulsion may 
enable hepatic administration of large dose of 
epirubicin with perhaps less systemic side effects.-' 
In conclusion,七he formulated emulsion demonstrates 
some important superior charatc七eristics when compared 
with the previous epirubicin - Lipiodol mixture. 
Further investigation and assessment are worthwhile for 
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Calibration for Epi And 130H 
Concn. Epi Peak Height Ratio 
125 0.07 
一 250 0.17 





Std Err of Y Est 0.029953 
R Squared 0.994287 
N o . of Observations 5 
Degrees of Freedom 4 
X Coefficient(s) 0.000533 
Std Err of Coef. 0.000012 








Std Err of Y Est 0.073289 
R Squared 0.998059 
N o . of Observations 5 
Degrees of Freedom 4 
X Coefficient(s) 0.002161 
Std Err of C o e f . 0.000031 








































































































































.. A p p e n d i x II 
Table (4) - 1 • 
Concentration of Epirubicin (ng/ml) in Emulsion 
Time (Hr)\Preparation Emulsion 1 Emulsion 2 Emulsion 3 Mean 土 SD 
0 9990.3 ‘ 9873.2 9520.9 9794.8 土 244 .3 
0.5 9080.3 9324.1 8980.2 9128.2 土 176-9 
1 7350.6 7805.2 7547.6 7567.8 土 228 .0 
1 .5 68已0.0 6543-2 6631.8 6685.0 土 174 .6 
2 6204.8 6450.2 6713 6546 土 2 5 4 . 1 
2 .5 6454.8 6330.2 6783 .1 6522.7 土 234 ,0 
3 6583 .1 6331.5 5843.已 6252.已 土 375 .9 
3 .5 5904.6 5846.3 7105,3 6285.4 土 710 .7 
4 6602.6 5200.3 6518.7 6107.2 土 786 .5 
4 .5 6502.3 5900.5 5454.4 5952.4 土 525 .9 
5 5869.3 5501.2 5937 .1 5769 .2 土 234 .6 
5 .5 5248.3 5580.2 5604.9 5477.8 土 1 9 9 . 1 




Concentration of Epirubicin (ng/ml) in Emulsion 
Time (Hr)\Preparat ion Emulsion 1 Emulsion 2 Emulsion 3 Mean 土 SD 
0 0 0 0 0 
0.5 0 0 0 0 
1 0 0 0 0 
1.5 0 350.9 294,7 322-8 土 39.7 
2 0 360.1 302.3 331.2 土 40.9 
2.5 102.3 285.5 299.5 229.1 土 110.0 
3 130.3 320.3 318.6 242.8 土 99.2 
3-5 150.2 370.5 329.8 283.5 土 117.2 
4 201 360.9 297.6 286.5 土 00.5 
4.5 250.2 378.2 342.4 . 323.6 土 66.0 
5 286.3 390-6 386.9 354.6 土 59.2 
5.5 300.1 410.6 4066.5 372.4 土 62.6 
’6 306.8 398.3 363.2 356.1 土 46-2 
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Concentration of Epirubicin (ng/ml) in Solution 
Time (Hr)\Preparation Solution 1 Solution 2 Solution 3 Mean 土 SD 
0 7502.3 7458.2 7141.1 7367.2 土 190.0 
0.5 6123.5 6850.2 6483.7 , 6485.8 土 363.4 
1 5304.2 5480.6 6367.7 5711.5 土 567.0 
1.5 4250.2 5023.6 4963.3 4745.7 土 430.2 
2 4050.3 5021.3 5165.5 4745.7 土 606.6 
•2.5 5620-1 4950.2 4344.8 4971.7 土 638.0 
3 4350.2 4512.6 4628.8 4497.1 土 139.7 
3 . 5 3 9 8 8 . 5 4 2 已 0 . 1 4 0 0 2 - 3 4 0 9 0 . 4 土 2 1 4 . 5 
4 3850.6 3955 3516.4 3774 土 229.1 
4.5 3650.1 3801.3 4073.4 3841.6 土 214.5 
5 3 5 0 0 3 4 1 2 . 3 5 5 0 3 . 5 4 1 3 8 . 6 土 1 1 8 2 . 9 
5 . 5 3405 .3 3502 .4 5 5 0 8 . 1 4 138 . 6 土 1187-0 
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Concentration of Epirubicin (ng/ml) in Solution 
Time(Hr)\Preparation Solution 1 Solution 2 Solution 3 Mean 土 SD 
0 0 0 0 “ 0 
0 . 5 217-8 230 .2 230 226 .0 土 7 . 1 
1 220-2 229 .8 228 226 .0 土 5 . 1 
1-5 278 .6 216 .9 3 1 8 . 1 161.7 土 124 .2 
2 286 .4 206 . 3 320 .9 271 .2 土 5 8 』 
2-5 250 .3 285 . 3 278 271 .2 土 18 .5 
3 289.4 296 .3 4 31 . 3 3390 土 80 . 0 
3-5 300.2 308 .6 272 .6 293 .8 土 18_8 
4 320.4 313 .3 315 .5 316 .4 土 3 . 6 
4 . 5 320-6 320 ,8 307 .8 316 .4 土 7 . 4 
5 330.8 350 .6 335 .6 339 .0 土 10 . 3 
5-5 380 .6 400 .8 439 406.8 土 29 . 7 
6 420 .4 4 2 0 . 1 447 .7 429.4 土 15 .8 
Concentration of Epirubicin (ng/ml) in Buffer Solution (Solution) 
.138 
Appendix III 
Plasma Concentration of Epirubicin (ng/ml) in 8 rabbits after IV injection of emulsion. 
\ Dose 
Time \ (ng) 1 2 3 4 5 6 7 8 Hean i SD 
(iiiQ.)\ 4.4 3.45 4.8 3.9 3.85 4.35 4.4 4,5 
2.5 327.9 88.1 271.8 110.8 905 571.4 194.2 362.4 353.9i270.9 
5 77.8 57.8 73.1 107.4 404 250 170.6 267.2 175,9+122.3 
10 18.2 23.1 42.7 62.3 204.1 214.3 130.2 180.2 109.4+82.7 
15 14.1 22 30.5 27.2 194.4 206.7 64.3 120.6 84.9+79.1 
30 10.2 14.8 154.5 200 57:3 54.3 81.8i77.8 
60 137.3 171.4 32.3 27.4 85,9+71.9 
120 62.3 62.3 12.2 4 5 . 6 J 8 . 9 
Plasna Concentration of Epiribicin (ng/Bil) in 8 rabbits after IV injection of solution 
\ Dose 
Time \ (mg) 1 2 3 4 5 6 7 8 Hean + SD 
(®in.)\ 4.5 4.2 4.1 3.9 4.8 4 4.5 4.3 
2.5 481.8 957.3 357.1 2521 783.3 362.4 486.4 864.3 851.7+712.8 
5 108.6 201.2 151.2 924.4 528.6 275.6 256 424.7 358.8+267.5 
iO 19 79.3 105-4 404.8 257.1 100.3 172 323.3 182.6+133.6 
15 16.7 67 85.7 267.2 200 62.4 74.5 303.2 134.6+106.9 
30 11.4 60.9 125. 185.7 ‘ 27.3 30.2 . . 127.8 81.2£65.6 
60 8.3 48.8 67.7 52.3 14.2 62.4 42.3+25.1 
120 42.7 25.4 34.1+12.2 
180 36.6 36.6 
139 
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Plasna Concentration of Epimbicin (ng/nl) in 10 rabbits after intrahepatic injection of emulsion 
\ Dose 
Time \ (ig) 1 2 3 4 5 6 7 8 9 10 Hean t SD 
4.2 4.5 4.3 4.5 4.5 4.4 3.6 3.9 4.5 4 
2.5 142,3 103 142.8 127.6 154.3 52.3 132.5 92.6 487.6 204.2 163.9+120.6 
5 70.6 28.6 51.9 74.2 42.1 25.5 20.2 17.4 158.9 100.2 58.9+44.3 
10 54.3 15.6 13.5 41.5 14.3 19.4 16.1 13,3 95.3 57.3 3 U i 2 7 . 6 
15 36.2 9.5 7.7 34.9 12.7 17.2 9.1 10.2 71 35.2 24.4+20.2 
30 32.4 7.7 29.7 11.5 15 17.4 18.9+9.9 
60 18.3 16.8 9,3 15.2 14.9i3.9 
120 11.7 l l . l 11.4+0.4 
P l a s M Concentration of Epirubicin (ng/nl) in 10 rabbits after intrahepatic injection of solution 
\ Dose 
Tiae \ (mg) 1 2 3 4 5 6 7 8 9 10 Hean t SD 
(fflin.A 4.5 4 4.45 4.2 4.5 4.3 4 3.9 4.6 4.1 
2.5 243.4 168.4 243.3 326,4 188.8 190.8 132.5 136 928.6 320.4 287.8+235.2 
5 127.1 52.7 52.1 82,7 34.8 56.6 39.8 27.4 317.3 180.2 97,1+90,8 
10 60.3 15.9 27.4 34,7 15.2 20,9 19.6 _ 13.5 147.6 90,3 44.5+43.7 
15 54.3 16.4 23.7 9.7 13.9 12.4 9.3 159.7 42.7 38.01i48.2 
30 37.3 23 U 12,2 11.3 9,1 12.4 i U i U J 
60 24.3 17.9 5.3 11.6 10.2 13.9f7.4 
120 12.1 12.1 
140 
• i , 






‘ ‘ .‘ - t； 
- . • 
- . . : • - . , ‘ ， . . . . 
• ；. •‘ • • 
。 . . . ...‘ .. 
:。::：::..-::'(),••: ： . 
•|i-.r.‘ ： V •.. •；•., . "I . 
•:〜、， 、：‘• I ‘ 心 . . 
CUHK L i b r a r i e s 
I 國 11圓11  ... 
•••3ESFL5M 
